Analyst Sara Nik of H.C. Wainwright reiterated a Buy rating on Cidara Therapeutics, retaining the price target of $150.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sara Nik’s rating is based on the promising clinical data from Cidara Therapeutics’ CD388, a non-vaccine candidate for preventing influenza. The recent Phase 2b clinical trial results presented during ID Week 2025 demonstrated that CD388 met its primary endpoint of preventive efficacy, showing significant protection against symptomatic influenza with a single subcutaneous dose. The updated data provided deeper insights into the drug’s efficacy, pharmacokinetics, and safety, which further validate the dose selection for the ongoing Phase 3 ANCHOR study.
Sara Nik emphasizes the importance of the detailed virology breakdown and the dose-dependent increase in preventive efficacy, particularly against influenza A. These findings support the continued development of CD388, especially for high-risk groups such as those with immune-compromised conditions or co-morbidities. The comprehensive safety profile and the mechanistic support from pharmacokinetic data further bolster confidence in CD388’s potential as a preventive treatment, justifying the Buy rating.
In another report released on October 16, Morgan Stanley also initiated coverage with a Buy rating on the stock with a $190.00 price target.